Who Paid My Doc
vixarelimab ulcerative colitis study
Research payments
$804,765
Through program year 2025, $804,765 in research payments was reported against vixarelimab ulcerative colitis study, across 126 payments, paid by Genentech, Inc..
- Paid by
- Genentech, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $425,723 | 75 |
| 2024 | Research | $379,043 | 51 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- George Duvall Tyler, TX Named on 12 payments
- Curtis Freedland Trinity, FL Named on 9 payments
- Mousab Tabbaa Westlake, OH Named on 9 payments
- John Valentine Gainesville, FL Named on 8 payments
- Lawrence Saubermann Rochester, NY Named on 7 payments
- Magued Beshay Mission Hills, CA Named on 6 payments
- Nathaniel Winstead Fairhope, AL Named on 6 payments
- Srikiran Pothamsetty Orlando, FL Named on 6 payments
- Ulric Duncan Southaven, MS Named on 5 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.